Citations

Showing 10 of 108081 citations.

Letter on “Natural history of pure autonomic failure: A United States prospective cohort”
Silber, Michael H. , Louis, Erik K. St. , St Louis, Erik K, Boeve, Bradley F. , St Louis, E K

Mayo Clinic

Annals of Neurology | May 4, 2017 | Volume: 81 | Issue: 6 | Pages: 910-910

10.1002/ana.24948 | PMID 28472851 Get It

Finding the grave of Sir William Richard Gowers
Toodayan, Nadeem , Lees, Andrew, Boes, Christopher J.

Mayo Clinic

Practical Neurology | May 4, 2017 | Volume: 17 | Issue: 4 | Pages: 321-322

10.1136/practneurol-2017-001648 | PMID 28473605 Get It

Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Ho, Yeung, Etten, Jamie L. Van, Yang, Rendong , Li, Yingming , Tseng, Elizabeth , Hon, Ting, Clark, Tyson A. , Tan, Winston , Carlson, Rachel E. , Wang, Liguo , Sicotte, Hugues , Ho, Thai H. , Jiménez, Rafael E. , Vedell, Peter T. , Eckloff, Bruce W., Quevedo, J. Fernando , Pitot, Henry C., Costello, Brian A. , Jen, Jin , Wieben, Eric D. , Silverstein, Kevin A.T. , Wang, Liewei , Dehm, Scott M. , Kohli, Manish , Thai, Ho, Jimenez, Rafael, Quevedo, Jorge F, Hillman, David W. , Henzler, Christine M. , Sperger, Jamie M. , Huang, Haojie , Lang, Joshua M. , Ho, Thai , Wang, Liguo , Dehm, Scott M

Mayo Clinic

Clinical Cancer Research | May 4, 2017 | Volume: 23 | Issue: 16 | Pages: 4704-4715

10.1158/1078-0432.ccr-17-0017 | PMID 28473535 Get It

Abstract Purpose: Androgen receptor (AR) variant AR-V7 is a ligand-independent transcription factor that promotes prostate cancer resistance to AR-targeted therapies. Accordingly, efforts are under way to develop strategies for monitoring and inhibiting AR-V7 in castration-resistant prostate cancer (CRPC). The purpose of this study was to understand whether other AR variants may be coexpressed with AR-V7 and promote resistance to AR-targeted therapies. Experimental Design: We utilized complementary short- and long-read sequencing of intact AR mRNA isoforms to characterize AR expression in CRPC models. Coexpression of AR-V7 and AR-V9 mRNA in CRPC metastases and circulating tumor cells was assessed by RNA-seq and RT-PCR, respectively. Expression of AR-V9 protein in CRPC models was evaluated with polyclonal antisera. Multivariate analysis was performed to test whether AR variant mRNA expression in metastatic tissues was associated with a 12-week progression-free survival endpoint in a prospective clinical trial of 78 CRPC-stage patients initiating therapy with the androgen synthesis inhibitor, abiraterone acetate. Results: AR-V9 was frequently coexpressed with AR-V7. Both AR variant species were found to share a common 3′ terminal cryptic exon, which rendered AR-V9 susceptible to experimental manipulations that were previously thought to target AR-V7 uniquely. AR-V9 promoted ligand-independent growth of prostate cancer cells. High AR-V9 mRNA expression in CRPC metastases was predictive of primary resistance to abiraterone acetate (HR = 4.0; 95% confidence interval, 1.31–12.2; P = 0.02). Conclusions: AR-V9 may be an important component of therapeutic resistance in CRPC. Clin Cancer Res; 23(16); 4704–15. ©2017 AACR.
Selective Arterial Calcium Stimulation With Hepatic Venous Sampling in Immune-Mediated Hypoglycemia
Service, F. John, Andrews, James C. , Thompson, Scott M. , Vella, Adrian

Mayo Clinic

Journal of the Endocrine Society | May 4, 2017 | Volume: 1 | Issue: 6 | Pages: 671-675

10.1210/js.2017-00146 | PMID 29264520 Get It

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report
Schriber, Jeffrey, Ahn, Kwang Woo , Fei, Mingwei , Costa, Luciano J. , Kharfan-Dabaja, M A, Angel-Diaz, Miguel, Ganguly, Siddharatha, Girnius, Saulius, Hashmi, Shahrukh K. , Pawarode, Attaphol , Vesole, David H. , Wiernik, Peter H. , Wirk, Baldeep , Marks, David I. , Olsson, Richard F. , Usmani, Saad Z. , D’Souza, Anita , Hashmi, Shahrukh, D'Souza, Anita , Hari, Parameswaran , Gale, Robert Peter , Nishihori, Taiga , Mark, Tomer M , Nieto, Yago , Olsson, Richard F , Costa, Luciano J , Usmani, Saad

Mayo Clinic

Cancer | May 4, 2017 | Volume: 123 | Issue: 16 | Pages: 3141-3149

10.1002/cncr.30747 | PMID 28472539 Get It

BACKGROUNDRace/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of autologous hematopoietic cell transplantation (AHCT) among patients with multiple myeloma (MM) and outcomes based on race/ethnicity in the United States.METHODSThe Center for International Blood and Marrow Transplant Research database was used to identify 28,450 patients who underwent AHCT for MM from 2008 through 2014. By using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 registries, the incidence of MM was calculated, and a stem cell transplantation utilization rate (STUR) was derived. Post‐AHCT outcomes were analyzed among patients ages 18 to 75 years who underwent melphalan‐conditioned peripheral cell grafts (N = 24,102).RESULTSThe STUR increased across all groups from 2008 to 2014. The increase was substantially lower among Hispanics (range, 8.6%‐16.9%) and non‐Hispanic blacks (range, 12.2%‐20.5%) compared with non‐Hispanic whites (range, 22.6%‐37.8%). There were 18,046 non‐Hispanic whites, 4123 non‐Hispanic blacks, and 1933 Hispanic patients. The Hispanic group was younger (P < .001). Fewer patients older than 60 years underwent transplantation among Hispanics (39%) and non‐Hispanic blacks (42%) compared with non‐Hispanic whites (56%). A Karnofsky score <90% and a hematopoietic cell transplantation comorbidity index score >3 were more common in non‐Hispanic blacks compared with Hispanic and non‐Hispanic whites (P < .001). More Hispanics (57%) versus non‐Hispanic blacks (54%) and non‐Hispanic whites (52%; P < .001) had stage III disease. More Hispanics (48%) versus non‐Hispanic blacks (45%) and non‐Hispanic whites (44%) had a very good partial response or better before transplantation (P = .005). Race/ethnicity did not impact post‐AHCT outcomes.CONCLUSIONSAlthough the STUR increased, it remained low and was significantly lower among Hispanics followed by non‐Hispanic blacks compared with non‐Hispanic whites. Race/ethnicity did not impact transplantation outcomes. Efforts to increase the rates of transplantation for eligible patients who have MM, with an emphasis on groups that underuse transplantation, are warranted. Cancer 2017;123:3141–9. © 2017 American Cancer Society.
Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy
Serie, Daniel, Necela, Brian M. , Axenfeld, Bianca, Dockter, Travis , Colón‐Otero, Gerardo , Perez, Edith A. , Thompson, E. Aubrey , Norton, Nadine , Serie, Daniel J, Crook, Julia E. , Axenfeld, Bianca C., Dockter, Travis J, Norton, Nadine

Mayo Clinic

Journal of Cardiovascular Development and Disease | May 4, 2017 | Volume: 4 | Issue: 2 | Pages: 6

10.3390/jcdd4020006 | PMID 29367538 Get It

Doxorubicin and the ERBB2 targeted therapy, trastuzumab, are routinely used in the treatment of HER2+ breast cancer. In mouse models, doxorubicin is known to cause cardiomyopathy and conditional cardiac knock out of Erbb2 results in dilated cardiomyopathy and increased sensitivity to doxorubicin-induced cell death. In humans, these drugs also result in cardiac phenotypes, but severity and reversibility is highly variable. We examined the association of decline in left ventricular ejection fraction (LVEF) at 15,204 single nucleotide polymorphisms (SNPs) spanning 72 cardiomyopathy genes, in 800 breast cancer patients who received doxorubicin and trastuzumab. For 7033 common SNPs (minor allele frequency (MAF) > 0.01) we performed single marker linear regression. For all SNPs, we performed gene-based testing with SNP-set (Sequence) Kernel Association Tests: SKAT, SKAT-O and SKAT-common/rare under rare variant non-burden; rare variant optimized burden and non-burden tests; and a combination of rare and common variants respectively. Single marker analyses identified seven missense variants in OBSCN (p = 0.0045–0.0009, MAF = 0.18–0.50) and two in TTN (both p = 0.04, MAF = 0.22). Gene-based rare variant analyses, SKAT and SKAT-O, performed very similarly (ILK, TCAP, DSC2, VCL, FXN, DSP and KCNQ1, p = 0.042–0.006). Gene-based tests of rare/common variants were significant at the nominal 5% level for OBSCN as well as TCAP, DSC2, VCL, NEXN, KCNJ2 and DMD (p = 0.044–0.008). Our results suggest that rare and common variants in OBSCN, as well as in other genes, could have modifying effects in cardiomyopathy.
Acute invasive hemodynamic effects of percutaneous mitral paravalvular leak closure
Lloyd, James W. , Rihal, Charanjit S. , Reeder, Guy S., Eleid, Mackram F. , Rihal, Charanjit S. , Nishimura, Rick A.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 4, 2017 | Volume: 90 | Issue: 5 | Pages: 851-858

10.1002/ccd.27093 | PMID 28471094 Get It

ObjectivesThe aim of this study was to demonstrate the physiologic effects of percutaneous mitral paravalvular leak (PVL) closure through pre‐ and post‐closure left and right heart catheterization.BackgroundMitral PVL represents a significant source of morbidity and mortality following mitral valve repair and replacement. Although percutaneous PVL closure is an effective treatment with improvements in symptoms and mortality, data regarding the acute hemodynamic effects of such closure are lacking.MethodsConsecutive patients with clinically significant heart failure and/or hemolysis attributed to mitral PVL underwent percutaneous mitral PVL closure with pre‐ and post‐procedural right and left heart catheterization. Hemodynamic measurements of cardiovascular function obtained in this manner were compared and stratified according to pre‐ and post‐procedural echocardiographic severity of PVL.ResultsTwenty‐four patients (age 68 ± 9.4 years, 75% male) underwent percutaneous mitral PVL closure. Significant improvements were found in left atrial pressure (LAP) (mean LAP lowered from 21 ± 4 to 19 ± 3 mm Hg, P = 0.005), pulmonary artery pressure (PAP) (mean PAP lowered from 36 ± 11 to 33 ± 9, P = 0.04), and cardiac index (increased from 2.8 ± 0.8 to 3.0 ± 0.7 L/min/m2, P = 0.01). Left atrial v‐wave reduction of 20% was associated with ≤ mild residual PVL by transesophageal echocardiography (P = 0.09).ConclusionsPercutaneous mitral PVL closure is associated with significant reductions in LAP and PAP and an increase in cardiac index. These hemodynamic effects underlie the clinical benefits of PVL closure and may be a useful tool for intraprocedural guidance. © 2017 Wiley Periodicals, Inc.
Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer
Iñiguez‐Ariza, Nicole M. , Ryder, Mabel , Hilger, Crystal, Bible, Keith C. , Ryder, Mabel M, Hilger, Crystal R, Ryder, Mabel

Mayo Clinic

Thyroid® | May 4, 2017 | Volume: 27 | Issue: 7 | Pages: 923-927

10.1089/thy.2016.0627 | PMID 28471306 Get It

Background: Historical anaplastic thyroid cancer (ATC) outcomes have been terrible, with a median survival of only five months and <20% one-year survival. Improved outcomes are now achieved with aggressive initial therapy in stages IVA and IVB disease, but patients with distant metastatic disease (stage IVC) still do poorly; improved therapies are sorely needed. Kinase inhibitors have emerged as promising agents in the therapy of advanced medullary and differentiated thyroid cancer, but there are limited data regarding the use of lenvatinib in ATC. The aim of this study was to delineate clinical outcomes in a series of patients with advanced ATC in response to lenvatinib therapy. Methods: A retrospective analysis was conducted involving all lenvatinib-treated Mayo Clinic ATC patients in 2015. Results: Of 28 distinct ATC patients seen in 2015, three (11%) with metastatic disease of ECOG performance status 2–3 were treated with lenvatinib. Two patients were male; age range at ATC diagnosis was 57–84 years. All three patients attained successful local control of their disease with surgery and/or combined chemoradiotherapy. Lenvatinib was offered as the second, third, or fourth line of therapy at the time of metastatic disease progression. Two patients incurred minor responses to therapy, with structural regression of distant metastatic tumor disease soon after starting lenvatinib treatment (at one to two months), while one patient achieved stable disease, but no Response Evaluation Criteria In Solid Tumors partial responses resulted. Overall survival after starting lenvatinib was two, six, and seven months. Fatigue and hypertension were prominent, and one patient developed pulmonary emboli while on lenvatinib. Conclusion: This initial single-institution experience suggests that lenvatinib may have some disease-modifying activity in metastatic ATC that is otherwise refractory to cytotoxic chemotherapy. Unfortunately, observed benefits were transient, and toxicities were prominent. Clinical trials are required to ascertain better the utility of lenvatinib in the management of advanced ATC.
Differentiating pulmonary transfusion reactions using recipient and transfusion factors
Looney, Mark R. , Keating, Sheila M. , Kor, Daryl J. , Lowell, Clifford A. , Hubmayr, Rolf D., Gropper, Michael A. , Koenigsberg, Monique, Wilson, Gregory , Matthay, Michael A. , Toy, Pearl, Murphy, Edward L. , Group, the TRALI Study, Hubmayr, Rolf, Wilson, Gregory A, Roubinian, Nareg H. , Gajic, Ognjen , Group, the TRALI Study

Mayo Clinic

Transfusion | May 4, 2017 | Volume: 57 | Issue: 7 | Pages: 1684-1690

10.1111/trf.14118 | PMID 28470756 Get It

BACKGROUNDIt is increasingly recognized that recipient risk factors play a prominent role in possible transfusion‐related acute lung injury (pTRALI) and transfusion‐associated circulatory overload (TACO). We hypothesized that both transfusion and recipient factors including natriuretic peptides could be used to distinguish TRALI from TACO and pTRALI.STUDY DESIGN AND METHODSWe performed a post hoc analysis of a case‐control study of pulmonary transfusion reactions conducted at the University of California at San Francisco and Mayo Clinic, Rochester. We evaluated clinical data and brain natriuretic peptides (BNP) levels drawn after transfusion in patients with TRALI (n = 21), pTRALI (n = 26), TACO (n = 22), and controls (n = 24). Logistic regression and receiver operating characteristics curve analyses were used to determine the accuracy of clinical and biomarker predictors in differentiating TRALI from TACO and pTRALI.RESULTSWe found that pTRALI and TACO were associated with older age, higher fluid balance, and elevated BNP levels relative to those of controls and TRALI. The following variables were useful in distinguishing cases of pTRALI and TACO from TRALI: age more than 70 years, BNP levels more than 1000 pg/mL, 24‐hour fluid balance of more than 3 L, and a lower number of transfused blood components. Using the above variables, our logistic model had a 91% negative predictive value in the differential diagnosis of TRALI.CONCLUSIONSModels incorporating readily available clinical and biomarker data can be used to differentiate transfusion‐related respiratory complications. Additional studies examining recipient risk factors and the likelihood of TRALI may be useful in decision making regarding donor white blood cell antibody testing.
Evaluation of COBAS AmpliPrep/COBAS TaqMan CMV Test for use in hematopoietic stem cell transplant recipients
Ramanan, Poornima , Ramanan, Poornima , Razonable, Raymund R.

Mayo Clinic

Expert Review of Molecular Diagnostics | May 4, 2017 | Volume: 17 | Issue: 7 | Pages: 633-639

10.1080/14737159.2017.1325737 | PMID 28468570 Get It